Azenta, Inc. (NASDAQ: AZTA) is a leading global provider of life sciences solutions, offering automated cold-chain sample management, biological storage, and multiomics services through its GENEWIZ business. Headquartered in Burlington, Massachusetts, the company supports leading pharmaceutical companies, biotechnology developers, and academic institutions worldwide. In October 2026, Azenta announced an operational restructuring within its Multiomics segment consolidating three North American lab sites, followed by strategic growth investments in cell-free DNA synthesis (licensing Elegen) and pooled gene libraries (acquiring SynPlexity).
Completion of Multiomics North American lab consolidation
Q4 FY2026 earnings release and financial outlook
Azenta, Inc. disclosed in an SEC Form 8-K (Item 2.05) a board-approved operational restructuring plan within its Multiomics reportable segment (GENEWIZ), enacting workforce reductions and permanently closing three North American laboratory sites. The site closures and headcount reductions streamline its North American laboratory footprint and improve operational efficiency, generating estimated pre-tax restructuring and asset impairment charges of $11.0M–$13.0M.
Azenta disclosed an SEC Form 8-K restructuring plan closing three North American Multiomics laboratory sites and cutting headcount, while announcing strategic investments including an Elegen cell-free DNA license and SynPlexity acquisition.
President and Chief Executive Officer
Executive Vice President and Chief Financial Officer